Cargando…

Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm

BACKGROUND: XCiDaBLE is a large, prospective, observational “naturalistic” study evaluating Xeomin® for Cervical Dystonia or BLEpharospasm in the United States. We report the interim results from the blepharospasm cohort of XCiDaBLE. METHODS: Subjects (≥18 years old) with blepharospasm were followed...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Hubert H., Jankovic, Joseph, Holds, John B., Lin, Daniel, Burns, John, Verma, Amit, Sethi, Kapil, Pappert, Eric J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia University Libraries/Information Services 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107228/
https://www.ncbi.nlm.nih.gov/pubmed/25120942
http://dx.doi.org/10.7916/D8MK6B1B
_version_ 1782327567756296192
author Fernandez, Hubert H.
Jankovic, Joseph
Holds, John B.
Lin, Daniel
Burns, John
Verma, Amit
Sethi, Kapil
Pappert, Eric J.
author_facet Fernandez, Hubert H.
Jankovic, Joseph
Holds, John B.
Lin, Daniel
Burns, John
Verma, Amit
Sethi, Kapil
Pappert, Eric J.
author_sort Fernandez, Hubert H.
collection PubMed
description BACKGROUND: XCiDaBLE is a large, prospective, observational “naturalistic” study evaluating Xeomin® for Cervical Dystonia or BLEpharospasm in the United States. We report the interim results from the blepharospasm cohort of XCiDaBLE. METHODS: Subjects (≥18 years old) with blepharospasm were followed for two treatment cycles of incobotulinumtoxinA and monitored for 4 weeks after injection via interactive voice/web response system (IVRS/IWRS). The investigator-reported scale includes the Clinical Global Impression Scale-Severity subscale (CGI-S). Patient-reported outcome measures include the Patient Global Impression Scale-Severity (PGI-S) and -Improvement (PGI-I) subscales, Jankovic Rating Scale (JRS), SF-12v2® health survey, and Work Productivity and Activity Impairment questionnaire. Subjects are seen by the investigator at baseline (including the first injection), during the second injection, and at a final study visit (12 weeks after the second injection). RESULTS: One hundred seventy subjects were included in this interim analysis. The majority of subjects were female (77.1%) and white (91.8%), and had previously been treated with botulinum toxins (96.5%). The mean total dose (both eyes) was 71.5 U of incobotulinumtoxinA for the first injection. PGI-S, PGI-I, and JRS scores were significantly improved 4 weeks after treatment (all p<0.0001). No differences were noted in either quality of life (QoL) or work productivity in this short assessment period. No unexpected adverse events occurred. DISCUSSION: This is an interim study and assessment method based on an IVRS/IWRS. In this predominantly toxin-experienced cohort, significant benefits in specific and global measures of disease severity were seen in the immediate post-incobotulinumtoxinA injection period. It will be interesting to see if there are improvements in QoL with consistent individualized injections over a longer period.
format Online
Article
Text
id pubmed-4107228
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Columbia University Libraries/Information Services
record_format MEDLINE/PubMed
spelling pubmed-41072282014-08-12 Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm Fernandez, Hubert H. Jankovic, Joseph Holds, John B. Lin, Daniel Burns, John Verma, Amit Sethi, Kapil Pappert, Eric J. Tremor Other Hyperkinet Mov (N Y) Articles BACKGROUND: XCiDaBLE is a large, prospective, observational “naturalistic” study evaluating Xeomin® for Cervical Dystonia or BLEpharospasm in the United States. We report the interim results from the blepharospasm cohort of XCiDaBLE. METHODS: Subjects (≥18 years old) with blepharospasm were followed for two treatment cycles of incobotulinumtoxinA and monitored for 4 weeks after injection via interactive voice/web response system (IVRS/IWRS). The investigator-reported scale includes the Clinical Global Impression Scale-Severity subscale (CGI-S). Patient-reported outcome measures include the Patient Global Impression Scale-Severity (PGI-S) and -Improvement (PGI-I) subscales, Jankovic Rating Scale (JRS), SF-12v2® health survey, and Work Productivity and Activity Impairment questionnaire. Subjects are seen by the investigator at baseline (including the first injection), during the second injection, and at a final study visit (12 weeks after the second injection). RESULTS: One hundred seventy subjects were included in this interim analysis. The majority of subjects were female (77.1%) and white (91.8%), and had previously been treated with botulinum toxins (96.5%). The mean total dose (both eyes) was 71.5 U of incobotulinumtoxinA for the first injection. PGI-S, PGI-I, and JRS scores were significantly improved 4 weeks after treatment (all p<0.0001). No differences were noted in either quality of life (QoL) or work productivity in this short assessment period. No unexpected adverse events occurred. DISCUSSION: This is an interim study and assessment method based on an IVRS/IWRS. In this predominantly toxin-experienced cohort, significant benefits in specific and global measures of disease severity were seen in the immediate post-incobotulinumtoxinA injection period. It will be interesting to see if there are improvements in QoL with consistent individualized injections over a longer period. Columbia University Libraries/Information Services 2014-07-16 /pmc/articles/PMC4107228/ /pubmed/25120942 http://dx.doi.org/10.7916/D8MK6B1B Text en http://creativecommons.org/licenses/by-nc-nd/3.0/us/ This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommerical–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original author and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.
spellingShingle Articles
Fernandez, Hubert H.
Jankovic, Joseph
Holds, John B.
Lin, Daniel
Burns, John
Verma, Amit
Sethi, Kapil
Pappert, Eric J.
Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm
title Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm
title_full Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm
title_fullStr Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm
title_full_unstemmed Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm
title_short Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm
title_sort observational study of incobotulinumtoxina for cervical dystonia or blepharospasm (xcidable): interim results for the first 170 subjects with blepharospasm
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107228/
https://www.ncbi.nlm.nih.gov/pubmed/25120942
http://dx.doi.org/10.7916/D8MK6B1B
work_keys_str_mv AT fernandezhuberth observationalstudyofincobotulinumtoxinaforcervicaldystoniaorblepharospasmxcidableinterimresultsforthefirst170subjectswithblepharospasm
AT jankovicjoseph observationalstudyofincobotulinumtoxinaforcervicaldystoniaorblepharospasmxcidableinterimresultsforthefirst170subjectswithblepharospasm
AT holdsjohnb observationalstudyofincobotulinumtoxinaforcervicaldystoniaorblepharospasmxcidableinterimresultsforthefirst170subjectswithblepharospasm
AT lindaniel observationalstudyofincobotulinumtoxinaforcervicaldystoniaorblepharospasmxcidableinterimresultsforthefirst170subjectswithblepharospasm
AT burnsjohn observationalstudyofincobotulinumtoxinaforcervicaldystoniaorblepharospasmxcidableinterimresultsforthefirst170subjectswithblepharospasm
AT vermaamit observationalstudyofincobotulinumtoxinaforcervicaldystoniaorblepharospasmxcidableinterimresultsforthefirst170subjectswithblepharospasm
AT sethikapil observationalstudyofincobotulinumtoxinaforcervicaldystoniaorblepharospasmxcidableinterimresultsforthefirst170subjectswithblepharospasm
AT pappertericj observationalstudyofincobotulinumtoxinaforcervicaldystoniaorblepharospasmxcidableinterimresultsforthefirst170subjectswithblepharospasm